Modeling neuroinflammatory pathogenesis of Parkinson's disease

Progress in Brain Research

Volumn 184, Issue C, 2010, Pages 113-132

  Barnum, Christopher J ^a   Tansey, Malú G ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Inflammation; LPS; Neurotoxin; Parkinson's disease; Stress; Substantia nigra; TNF

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; LIPOPOLYSACCHARIDE; OXIDOPAMINE; PESTICIDE;

AGING; BOOK; CELL DEATH; CHRONIC DISEASE; DISEASE COURSE; DOPAMINERGIC NERVE CELL; EXCITOTOXICITY; INFLAMMATION; MENTAL STRESS; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

EID: 77957235446     PISSN: 00796123     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0079-6123(10)84006-3     Document Type: Chapter

References (153)

1. Arimoto T., Bing G. Up-regulation of inducible nitric oxide synthase in the substantia nigra by lipopolysaccharide causes microglial activation and neurodegeneration. Neurobiology of Disease 2003, 12:35-45.
2. Armentero M.T., Levandis G., Nappi G., Bazzini E., Blandini F. Peripheral inflammation and neuroprotection: Systemic pretreatment with complete Freund's adjuvant reduces 6-hydroxydopamine toxicity in a rodent model of Parkinson's disease. Neurobiology of Disease 2006, 24(3):492-505.
3. Baldereschi M., Inzitari M., Vanni P., Di Carlo A., Inzitari D. Pesticide exposure might be a strong risk factor for Parkinson's disease. Annals of Neurology 2008, 63(1):128.
4. Basuroy S., Bhattacharya S., Leffler C.W., Parfenova H. Nox4 NADPH oxidase mediates oxidative stress and apoptosis caused by TNFlpha in cerebral vascular endothelial cells. American Journal of Physiology 2009, 296(3):C422-C432.
5. Blandino P., Barnum C.J., Deak T. The involvement of norepinephrine and microglia in hypothalamic and splenic IL-1Β beta responses to stress. Journal of Neuroimmunology 2006, 173:87-95.
6. Blandino P., Barnum C.J., Solomon L.G., Larish Y., Lankow B.S., Deak T. Gene expression changes in the hypothalamus provide evidence for regionally-selective changes in IL-1Β and microglial markers after acute stress. Brain, Behavior, and Immunity 2009, 23(7):958-968.
7. Block M.L., Hong J.S. Microglia and inflammation-mediated neurodegeneration: Multiple triggers with a common mechanism. Progress in Neurobiology 2005, 76(2):77-98.
8. Braak H., Rub U., Gai W.P., Del Tredici K. Idiopathic Parkinson's disease: Possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. Journal of Neural Transmission 2003, 110(5):517-536.
9. Bronstein D., Perez-Otano I., Sun V., Mullis Sawin S., Chan J., Wu G., et al. Glia-dependent neurotoxicity and neuroprotection in mesencephalic cultures. Brain Research 1995, 704(1):112-116.
10. Cannon J.R., Tapias V., Na H.M., Honick A.S., Drolet R.E., Greenamyre J.T. A highly reproducible rotenone model of Parkinson's disease. Neurobiology of Disease 2009, 34(2):279-290.
11. Carvey P.M., Chang Q., Lipton J.W., Ling Z. Prenatal exposure to the bacteriotoxin lipopolysaccharide leads to long-term losses of dopamine neurons in offspring: A potential, new model of Parkinson's disease. Frontiers in Bioscience 2003, 8:s826-s837.
12. Carvey P., Punati A., Newman M. Progressive dopamine neuron loss in Parkinson's disease: The multiple hit hypothesis. Cell Transplantation 2006, 15:239-250.
13. Casarejos M.J., Menéndez J., Solano R.M., Rodríguez-Navarro J.A., García de Yébenes J., Mena M.A. Susceptibility to rotenone is increased in neurons from parkin null mice and is reduced by minocycline. Journal of Neurochemistry 2006, 97(4):934-946.
14. Castano A., Herrera A., Cano J., Machado A. Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. Journal of Neurochemistry 1998, 70(4):1584-1592.
15. Chen H., Jacobs E., Schwarzschild M.A., McCullough M.L., Calle E.E., Thun M.J., et al. Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Annals of Neurology 2005, 58(6):963-967.
16. Chen H., Zhang S.M., Hernán M.A., Schwarzschild M.A., Willett W.C., Colditz G.A., et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Archives of Neurology 2003, 60(8):1059-1064.
17. Cho L., Tsunoda M., Sharma R.P. Effects of endotoxin and tumor necrosis factor alpha on regional brain neurotransmitters in mice. Natural Toxins 1999, 7(5):187-195.
18. Choi D.-Y., Liu M., Hunter R.L., Cass W.A., Pandya J.D., Sullivan P.G., et al. Striatal neuroinflammation promotes Parkinsonism in rats. PLoS ONE 2009, 4(5):e5482.
19. Chung H.Y., Cesari M., Anton S., Marzetti E., Giovannini S., Seo A.Y., et al. Molecular inflammation: Underpinnings of aging and age-related diseases. Ageing Research Reviews 2009, 8(1):18-30.
20. Cicchetti F., Brownell A.L., Williams K., Chen Y.I., Livni E., Isacson O. Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. European Journal of Neuroscience 2002, 15(6):991-998.
21. Cicchetti F., Drouin-Ouellet J., Gross R.E. Environmental toxins and Parkinson's disease: What have we learned from pesticide-induced animal models?. Trends in Pharmacological Sciences 2009, 30(9):475-483.
22. Colton C.A. Heterogeneity of microglial activation in the innate immune response in the brain. Journal of Neuroimmune Pharmacology 2009, 4(4):399-418.
23. Cunnigham C., Wilcockson D., Campion S., Lunnon K., Perry V. Central and systemic endotoxin challenges exacerbate the local inflammatory response and increases neuronal death during chronic neurodegeneration. Neurobiology of Disease 2005, 25(40):9275-9284.
24. Dale R.C., Church A.J., Surtees R.A., Lees A.J., Adcock J.E., Harding B., et al. Encephalitis lethargica syndrome: 20 new cases and evidence of basal ganglia autoimmunity. Brain 2004, 127(1):21-33.
25. Dauer W., Przedborski S. Parkinson's disease: Mechanisms and models. Neuron 2003, 39:889-909.
26. De Kloet E.R., Vreugdenhil E., Oitzl M.S., Joels M. Brain corticosteroid receptor balance in health and disease. Endocrine Reviews 1998, 19(3):269-301.
27. De Lella Ezcurra A.L., Chertoff M., Ferrari C., Graciarena M., Pitossi F. Chronic expression of low levels of tumor necrosis factor-alpha in the substantia nigra elicits progressive neurodegeneration, delayed motor symptoms and microglia/macrophage activation. Neurobiology of Disease 2010, 37(3):630-640.
28. De Martinis M., Franceschi C., Monti D., Ginaldi L. Inflamm-ageing and lifelong antigenic load as major determinants of ageing rate and longevity. FEBS Letters 2005, 579(10):2035-2039.
29. De Pablos R.M., Herrera A.J., Villaran R.F., Cano J., Machado A. Dopamine-dependent neurotoxicity of lipopolysaccharide in substantia nigra. FASEB Journal 2005, 19(3):407-409.
30. Deak T. From classic aspects of the stress response to neuroinflammation and sickness: Implications for individuals and offspring. International Journal of Comparative Psychology 2007, 20:96-110.
31. Deak T., Bellamy C., D'Agostine L. Exposure to forced swim stress does not alter central production of IL-1Β. Brain Research 2003, 972:53-63.
32. Deak T., Bordner K., McElderry N., Barnum C., Blandino P., Deak M., et al. Stress-induced increases in hypothalamic IL-1Β: A systematic analysis of multiple stressor paradigms. Brain Research Bulletin 2005, 64:541-556.
33. Dehmer T., Lindenau J., Haid S., Dichgans J., Schulz J.B. Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. Journal of Neurochemistry 2000, 74(5):2213-2216.
34. Dhillon A.S., Tarbutton G.L., Levin J.L., Plotkin G.M., Lowry L.K., Nalbone J.T., et al. Pesticide/environmental exposures and Parkinson's disease in East Texas. Journal of Agromedicine 2008, 13(1):37-48.
35. Drolet R.E., Cannon J.R., Montero L., Greenamyre J.T. Chronic rotenone exposure reproduces Parkinson's disease gastrointestinal neuropathology. Neurobiology of Disease 2009, 36(1):96-102.
36. Du Y., Ma Z., Lin S., Dodel R., Gao F., Bales K., et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America 2001, 98(25):14669-14674.
37. Ferrari C.C., Pott Godoy M.C., Tarelli R., Chertoff M., Depino A.M., Pitossi F.J. Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1Β in the substantia nigra. Neurobiology of Disease 2006, 24(1):183-193.
38. Franceschi C., Valensin S., Fagnoni F., Barbi C., Bonafe M. Biomarkers of immunosenescence within an evolutionary perspective: The challenge of heterogeneity and the role of antigenic load. Experimental Gerontology 1999, 34(8):911-921.
39. Frank M., Baratta M., Sprunger D., Watkins L., Maier S. Microglia serve as a neuroimmune substrate for stress-induced potentiation of CNS pro-inflammatory cytokine responses. Brain, Behavior, and Immunity 2006, 21(1):47-59.
40. Frank-Cannon T.C., Tran T., Ruhn K.A., Martinez T.N., Hong J., Marvin M., et al. Parkin deficiency increases vulnerabiity to inflammation-related nigral degeneration. Journal of Neuroscience 2008, 28(43):10825-10834.
41. Gao H.M., Hong J.S. Why neurodegenerative diseases are progressive: Uncontrolled inflammation drives disease progression. Trends in Immunology 2008, 29(8):357-365.
42. Gao H.-M., Hong J.-S., Zhang W., Liu B. Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. Journal of Neuroscience 2002, 22(3):782-790.
43. Gao H., Hong J., Zhang W., Liu B. The Journal of Neuroscience. Synergistic dopaminergic neurotoxicity of the pesticide rotenonte and inflammogen lipopolysaccharide: Relevance to the etiology of Parkinson's disease 2003, 23(4):1228-1236.
44. Gao H.M., Jiang J., Wilson B., Zhang W., Hong J.S., Liu B. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: Relevance to Parkinson's disease. Journal of Neurochemistry 2002, 81(6):1285-1297.
45. Gao H., Liu B., Zhang W., Hong J. FASEB Journal. Synergistic dopaminergic neurotoxicity of MPTP and inflammogen lipopolysaccharide: Relevance to the etiology of Parkinson's disease 2003, 17:1957-1959.
46. Garcia-Bueno B., Madrigal J.L., Perez-Nievas B.G., Leza J.C. Stress mediators regulate brain prostaglandin synthesis and peroxisome proliferator-activated receptor-gamma activation after stress in rats. Endocrinology 2008, 149(4):1969-1978.
47. Gifford G., Lohmann-Matthes M. Gamma-interferon priming of mouse and human macrophages for induction of tumor necrosis factor production by bacterial lipopolysaccharide. Journal of the National Cancer Institute 1987, 78:121-124.
48. Greenamyre J.T., Cannon J.R., Drolet R., Mastroberardino P.-G. Lessons from the rotenone model of Parkinson's disease. Trends in Pharmacological Sciences 2010, 31(4):142-143.
49. Hamaue N., Ogata A., Terado M., Ohno K., Kikuchi S., Sasaki H., et al. Brain catecholamine alterations and pathological features with aging in Parkinson disease model rat induced by Japanese encephalitis virus. Neurochemical Research 2006, 31(12):1451-1455.
50. Hancock D.B., Martin E.R., Mayhew G.M., Stajich J.M., Jewett R., Stacy M.A., et al. Pesticide exposure and risk of Parkinson's disease: A family-based case-control study. BioMedCentral Neurology 2008, 8:6.
51. He Y., Appel S., Le W. Minocycline inhibits microglial activation and protects nigral cells after 6-OHDA injection into mouse striatum. Brain Research 2001, 909(1-2):187-193.
52. Herrera A., Castano A., Venero J., Cano J., Machado A. The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reaction on dopaminergic system. Neurobiology of Disease 2000, 7:429-447.
53. Hirsch E., Hunot S., Damier P., Faucheux B. Glial cells and inflammation in Parkinson's disease: A role in neurodegeneration?. Annals of Neurology 1998, 44:S115-S120.
54. Hunter R., Dragicevic N., Seifert K., Choi D., Lui M., Kim H., et al. Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system. Journal of Neurochemistry 2007, 100(5):1375-1386.
55. Ichikawa H., Takagi T., Uchiyama K., Higashihara H., Katada K., Isozaki Y., et al. Rotenone, a mitochondrial electron transport inhibitor, ameliorates ischemia-reperfusion-induced intestinal mucosal damage in rats. Redox Report 2004, 9(6):313-316.
56. Jang H., Boltz D., Sturm-Ramirez K., Shepherd K.R., Jiao Y., Webster R., et al. Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegeneration. Proceedings of the National Academy of Sciences of the United States of America 2009, 106(33):14063-14068.
57. Jang H., Boltz D.A., Webster R.G., Smeyne R.J. Viral parkinsonism. Biochimica et Biophysica Acta 2009, 1792(7):714-721.
58. Jankovic J., Stacy M. Medical management of levodopa-associated motor complications in patients with Parkinson's disease. CNS Drugs 2007, 21(8):677-692.
59. Jenner P., Olanow C.W. The pathogenesis of cell death in Parkinson's disease. Neurology 2006, 66(10 Suppl. 4):S24-S36.
60. Josephs K.A., Parisi J.E., Dickson D.W. Alpha-synuclein studies are negative in postencephalic parkinsonism of von Economo. Neurology 2002, 59(4):645-646.
61. Kamel F., Tanner C., Umbach D., Hoppin J., Alavanja M., Blair A., et al. Pesticide exposure and self-reported Parkinson's disease in the agricultural health study. American Journal of Epidemiology 2006, 165(4):364-374.
62. Kaneko Y.S., Mori K., Nakashima A., Sawada M., Nagatsu I., Ota A. Peripheral injection of lipopolysaccharide enhances expression of inflammatory cytokines in murine locus coeruleus: Possible role of increased norepinephrine turnover. Journal of Neurochemistry 2005, 94(2):393-404.
63. Kim Y., Joh T. Microglia, major player in the brain inflammation: Their roles in the pathogenesis of Parkinson's disease. Experimental and Molecular Medicine 2006, 38(4):333-347.
64. Kim W., Mahoney R., Wilson B., Jeohn G., Liu B., Hong J. Regional differences in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: Role of microglia. Journal of Neuroscience 2000, 20:6309-6316.
65. Kitazawa M., Oddo S., Yamasaki T.R., Green K.N., LaFerla F.M. Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. Journal of Neuroscience 2005, 25(39):8843-8853.
66. Knot C., Stern G., Wilkin G. Inflammatory regulators in Parkinson's disease: i NOS, lipocortin-1, and cyclooxygenase-1 and-2. Molecular and Cellular Neuroscience 2000, 16:724-739.
67. Ko S., Kwok T.T., Fung K.P., Choy Y.M., Lee C.Y., Kong S.K. Tumour necrosis factor induced an early release of superoxide and a late mitochondrial membrane depolarization in L929 cells. Increase in the production of superoxide is not sufficient to mimic the action of TNF. Biological Signals and Receptors 2001, 10(5):326-335.
68. Koprich J.B., Reske-Nielsen C., Mithal P., Isacson O. Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease. Journal of Neuroinflammation 2008, 5:8.
69. Lawson L., Perry V., Dri P., Gordon S. Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 1990, 39:151-170.
70. Liberatore G.T., Jackson-Lewis V., Vukosavic S., Mandir A.S., Vila M., McAuliffe W.G., et al. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nature Medicine 1999, 5(12):1403-1409.
71. Lin S., Wei X., Xu Y., Yan C., Dodel R., Zhang Y., et al. Minocycline blocks 6-hydroxydopamine-induced neurotoxicity and free radical production in rat cerebellar granule neurons. Life Sciences 2003, 72(14):1635-1641.
72. Ling Z., Chang Q., Lipton J., Tong C., Landers T., Carvey P. Combined toxicity of prenatal bacterial endotoxin exposure and postnatal 6-hydroxydopamine in the adult rat midbrain. Neuroscience 2004, 124:619-628.
73. Ling Z., Zhu Y., Tong C., Snyder J., Lipton J., Carvey P. Progressive dopamine neuron loss following supra-nigral lipopolysaccharide (LPS) infusion into rats exposed to LPS prenatally. Experimental Neurology 2006, 199:499-512.
74. Liou H.H., Chen R.C., Tsai Y.F., Chen W.P., Chang Y.C., Tsai M.C. Effects of paraquat on the substantia nigra of the Wistar rats: Neurochemical, histological, and behavioral studies. Toxicology and Applied Pharmacology 1996, 137(1):34-41.
75. Liu B., Gao H.-M., Hong J.-S. Parkinson's disease and exposure to infectious agents and pesticides and the occurrence of brain injuries: Role of neuroinflammation. Environmental Health Perspectives 2003, 111(8):1065-1073.
76. Luthman J., Fredriksson A., Sundstrom E., Jonsson G., Archer T. Selective lesion of central dopamine or noradrenaline neuron systems in the neonatal rat: Motor behavior and monoamine alterations at adult stage. Behavioural Brain Research 1989, 33(3):267-277.
77. Macht M., Ellgring H. Behavioral analysis of the freezing phenomenon in Parkinson's disease: A case study. Journal of Behavior Therapy and Experimental Psychiatry 1999, 30(3):241-247.
78. Macht M., Schwarz R., Ellgring H. Patterns of psychological problems in Parkinson's disease. Acta Neurologica Scandinavica 2005, 111:95-101.
79. Mangano E.N., Hayley S. Inflammatory priming of the substantia nigra influences the impact of later paraquat exposure: Neuroimmune sensitization of neurodegeneration. Neurobiology of Aging 2009, 30(9):1361-1378.
80. Manning-Bog A.B., McCormack A.L., Li J., Uversky V.N., Fink A.L., Di Monte D.A. The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: Paraquat and alpha-synuclein. Journal of Biological Chemistry 2002, 277(3):1641-1644.
81. Mao H., Liu B. Synergistic microglial reactive oxygen species generation induced by pesticides lindane and dieldrin. Neuroreport 2008, 19(13):1317-1320.
82. Marsden C., Owen D. Mechanisms underlying emotional variation in parkinsonian tremor. Neurology 1967, 17(7):711-715.
83. McCormack A.L., Thiruchelvam M., Manning-Bog A.B., Thiffault C., Langston J.W., Cory-Slechta D.A., et al. Environmental risk factors and Parkinson's disease: Selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiology of Disease 2002, 10(2):119-127.
84. McCoy M., Martinez T., Ruhn K., Szymkowski D., Smith C., Botterman B., et al. Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease. The Journal of Neuroscience 2006, 26(37):9365-9375.
85. McGeer P., Itagaki S., Botes B., McGeer E. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988, 38:1285-1291.
86. McGeer P., McGeer E. Inflammation and the degenerative diseases of aging. Annals of the New York Academy of Sciences 2004, 1035:104-116.
87. Miller R.L., James-Kracke M., Sun G.Y., Sun A.Y. Oxidative and inflammatory pathways in Parkinson's disease. Neurochemical Research 2009, 34(1):55-65.
88. Mittelbronn M., Dietz K., Schluesener H., Meyermann R. Local distribution of microglia in the normal adult human central nervous system differs by up to one order of magnitude. Acta Neuropathologica 2001, 101:249-255.
89. Mogi M., Harada M., Kondo T., Riederer P., Nagatsu T. Brain beta 2-microglobulin levels are elevated in the striatum in Parkinson's disease. Journal of Neural Transmission Parkinsons Disease and Dementia Section 1995, 9:87-92.
90. Mogi M., Harada M., Riederer P., Narabyashi H., Fujita J., Nagatsu T. Interleukin-1 beta growth factor and transforming growth factor-alpha are elevated in the brain from Parkinsonian patients. Neuroscience Letters 1994, 180:147-150.
91. Mogi M., Togari A., Tanaka K., Ogawa N., Ichinose H., Nagatsu T. Increase in level of tumor necrosis factor (TNF)-alpha in 6-hydroxydopamine-lesioned striatum in rats without influence of systemic l-DOPA on the TNF-alpha induction. Neuroscience Letters 1999, 268(2):101-104.
92. Molina-Holgado F., Guaza C. Endotoxin administration induced differential neurochemical activation of the rat brain stem nuclei. Brain Research Bulletin 1996, 40(3):151-156.
93. Mori K., Kaneko Y.S., Nakashima A., Nagatsu I., Takahashi H., Ota A. Peripheral lipopolysaccharide induces apoptosis in the murine olfactory bulb. Brain Research 2005, 1039(1-2):116-129.
94. Morrow L., McClellan J., Conn C., Kluger M. Glucocorticoids alter fever and IL-6 responses to psychological stress and to lipopolysaccharide. American Journal of Physiology 1993, 264(5 pt 2):R1010-R1016.
95. Mount M., Lira A., Grimes D., Smith P., Faucher S., Slack R., et al. Involvement of interferon gamma in microglial-mediated loss of dopaminergic neurons. The Journal of Neuroscience 2007, 27(12):3328-3337.
96. Na S.J., Dilella A.G., Lis E.V., Jones K., Levine D.M., Stone D.J., et al. Molecular profiling of a 6-hydroxydopamine model of Parkinson's disease. Neurochemical Research 2010, 35(5):761-772.
97. Nagatsu T., Sawada M. Inflammatory process in Parkinson's disease: Role for cytokines. Current Pharmaceutical Design 2005, 11:999-1016.
98. Nguyen K., Deak T., Owens S., Kohno T., Fleshner M., Watkins L., et al. Exposure ot acute stress induces brain interleukin-1 beta protein in the rat. The Journal of Neuroscience 1998, 18(6):2239-2246.
99. O'Callaghan J.P., Sriram K., Miller D.B. Defining "neuroinflammation". Annals of the New York Academy of Sciences 2008, 1139:318-330.
100. O'Connor K., Johnson J., Hansen M., Wieseler Frank J., Maksimova E., Watkins L., et al. Peripheral and central proinflammatory cytokine response to a severe acute stressor. Brain Research 2003, 991:123-132.
101. Ogata A., Tashiro K., Nukuzuma S., Nagashima K., Hall W.W. A rat model of Parkinson's disease induced by Japanese encephalitis virus. Journal of Neurovirology 1997, 3(2):141-147.
102. Oiwa Y., Sanchez-Pernaute R., Harvey-White J., Bankiewicz K.S. Progressive and extensive dopaminergic degeneration induced by convection-enhanced delivery of 6-hydroxydopamine into the rat striatum: A novel rodent model of Parkinson disease. Journal of Neurosurgery 2003, 98(1):136-144.
103. Ota A., Mori K., Kaneko Y.S., Nakashima A., Nagatsu I., Nagatsu T. Peripheral lipopolysaccharide administration affects the olfactory dopamine system in mice. Annals of the New York Academy of Sciences 2008, 1148:127-135.
104. Pawelec G., Ouyang Q., Colonna-Romano G., Candore G., Lio D., Caruso C. Is human immunosenescence clinically relevant? Looking for 'immunological risk phenotypes'. Trends in Immunology 2002, 23(7):330-332.
105. Peng J., Mao X.O., Stevenson F.F., Hsu M., Andersen J.K. The herbicide paraquat induces dopaminergic nigral apoptosis through sustained activation of the JNK pathway. Journal of Biological Chemistry 2004, 279(31):32626-32632.
106. Perry V. The influence of systemic inflammation on inflammation in the brain: Implications for chronic neurodegenerative disease. Brain, Behavior, and Immunity 2004, 18:407-413.
107. Perry V., Cunningham C., Holmes C. Systemic infections and inflammation affect chronic neurodegeneration. Nature Reviews Immunology 2007, 7(2):161-167.
108. Phinney A.L., Andringa G., Bol J.G.J.M., Wolters E.C., van Muiswinkel F.L., van Dam A.-M.W., et al. Enhanced sensitivity of dopaminergic neurons to rotenone-induced toxicity with aging. Parkinsonism and Related Disorders 2006, 12(4):228-238.
109. Purisai M.G., McCormack A.L., Cumine S., Li J., Isla M.Z., Di Monte D.A. Microglial activation as a priming event leading to paraquat-induced dopaminergic cell degeneration. Neurobiology of Disease 2007, 25(2):392-400.
110. Qin L., Liu Y., Wang T., Wei S.-J., Block M., Wilson B., et al. NAPDH oxidase mediates lipopolysaccharide-induced neurotoxicity and proinflammatory gene expression in activated microglia. The Journal of Biological Chemistry 2004, 279(2):1415-1421.
111. Qin L., Wu X., Block M.L., Liu Y., Breese G.R., Hong J.-S., et al. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 2007, 55(5):453-462.
112. Quintero E.M., Willis L., Singleton R., Harris N., Huang P., Bhat N., et al. Behavioral and morphological effects of minocycline in the 6-hydroxydopamine rat model of Parkinson's disease. Brain Research 2006, 1093(1):198-207.
113. Radad K., Rausch W.-D., Gille G. Rotenone induces cell death in primary dopaminergic culture by increasing ROS production and inhibiting mitochondrial respiration. Neurochemistry International 2006, 49(4):379-386.
114. Ransohoff R.M., Perry V.H. Microglial physiology: Unique stimuli, specialized responses. Annual Review of Immunology 2009, 27:119-145.
115. Ransom B.R., Kunis D.M., Irwin I., Langston J.W. Astrocytes convert the parkinsonism inducing neurotoxin, MPTP, to its active metabolite, MPP+. Neuroscience Letters 1987, 75(3):323-328.
116. Rothwell N. Interleukin-1 and neuronal injury: Mechanisms, modification, and therapeutic potential. Brain, Behavior, and Immunity 2003, 17:152-157.
117. Rothwell N., Luheshi G. Interleukin 1 in the brain: Biology, pathology and therapeutic target. Trends in Neuroscience 2000, 23(12):618-625.
118. Rugbjerg K., Friis S., Ritz B., Schernhammer E.S., Korbo L., Olsen J.H. Autoimmune disease and risk for Parkinson disease: A population-based case-control study. Neurology 2009, 73(18):1462-1468.
119. Saint-Pierre M., Tremblay M.-E., Sik A., Gross R.E., Cicchetti F. Temporal effects of paraquat/maneb on microglial activation and dopamine neuronal loss in older rats. Journal of Neurochemistry 2006, 98(3):760-772.
120. Samii A., Etminan M., Wiens M.O., Jafari S. NSAID use and the risk of Parkinson's disease: Systematic review and meta-analysis of observational studies. Drugs Aging 2009, 26(9):769-779.
121. Saura J., Pares M., Bove J., Pezzi S., Alberch J., Marin C., et al. Intranigral infusion of interleukin-1beta activates astrocytes and protects from subsequent 6-hydroxydopamine neurotoxicity. Journal of Neurochemistry 2003, 85(3):651-661.
122. Schmidt W., Alam M. Controversies on new animal models of Parkinson's disease pro and con: The rotenone model of Parkinson's disease (PD). Journal of Neural Transmission. Supplementum 2006, 70:273-276.
123. Schober A. Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Research 2004, 318(1):215-224.
124. Schwab R., Zieper I. Effects of mood, motivation, stress and alterness on the performance in Parkinson's disease. Psychiatry and Neurology 1965, 150:345-357.
125. Seroogy, K., Dolgas, C., Lundgren, K., & Herman, J. (2006). Chronic unpredictable stress exacerbates nigral dopaminergic neuron degeneration in a partial lesion model Rof Parkinson's disease. In 2006 Neuroscience Meeting Planner. Atlanta, GA: Society for Neuroscience (Online).
126. Sherer T.B., Betarbet R., Kim J.H., Greenamyre J.T. Selective microglial activation in the rat rotenone model of Parkinson's disease. Neuroscience Letters 2003, 341(2):87-90.
127. Shih, Y. T., Chen, I. J., Wu, Y. C., & Lo, Y. C. (2009). San-Huang-Xie-Xin-Tang protects against activated microglia- and 6-OHDA-induced toxicity in neuronal SH-SY5Y cells. Evidence-Based Complementary and Alternative Medicine [Epub ahead of print].
128. Shoji H., Watanabe M., Itoh S., Kuwahara H., Hattori F. Japanese encephalitis and parkinsonism. Journal of Neurology 1993, 240(1):59-60.
129. Smeyne R.J., Jackson-Lewis V. The MPTP model of Parkinson's disease. Brain Research Molecular Brain Research 2005, 134(1):57-66.
130. Smith A., Castro S., Zigmond M. Stress-induced Parkinson's disease: A working hypothesis. Physiology and Behavior 2002, 77:527-531.
131. Snyder A., Stricker E., Zigmond M. Stress-induced neurological impairments in an animal model of parkinsonism. Annals of Neurology 1985, 18(5):544-551.
132. Spoor M.S., Radi Z.A., Dunstan R.W. Characterization of age- and gender-related changes in the spleen and thymus from control cynomolgus macaques used in toxicity studies. Toxicologic Pathology 2008, 36(5):695-704.
133. Sriram K., Matheson J., Benkovic S., Miller D., Luster M., O'Callaghan J. Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: Implications for Parkinson's disease. Federation of American Societies for Experimental Biology 2002, 16(11):1474-1476.
134. Sulzer D. Multiple hit hypothesis for dopamine neuron loss in Parkinson's disease. Trends in Neuroscience 2007, 30(5):244-250.
135. Suzuki E., Shintani F., Kanba S., Asai M., Nakaki T. Immobilization stress increases mRNA levels of interleukin-1 receptor antagonist in various rat brain regions. Cellular and Molecular Neurobiology 1997, 17(5):557-562.
136. Tansey M., McCoy M., Frank-Cannon T. Neuroinflammatory mechanisms in Parkinson's disease: Potential environmental triggers, pathways, and targets for early therapeutic intervention. Experimental Neurology 2007, 208(1):1-25.
137. Thiruchelvam M., Brockel B., Richfield E., Baggs R., Cory-Slechta D. Potentiated and preferential effects of combined paraquat and maneb on nigrostriatal dopamine systems: Environmental risk factors for Parkinson's disease?. Brain Research 2000, 873:225-234.
138. Thiruchelvam M., Richfield E.K., Baggs R.B., Tank A.W., Cory-Slechta D.A. The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: Implications for Parkinson's disease. Journal of Neuroscience 2000, 20(24):9207-9214.
139. Thomas B., Beal M.F. Parkinson's disease. Human Molecular Genetics 2007, 16 Spec(2):R183-R194.
140. Ungerstedt U. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. European Journal of Pharmacology 1968, 5:107-110.
141. Viviani B., Bartesaghi S., Corsini E., Galli C., Marinovich M. Cytokines role in neurodegenerative events. Toxicology Letters 2004, 149:85-89.
142. Weiner W.J. Motor fluctuations in Parkinson's disease. Reviews in Neurological Diseases 2006, 3(3):101-108.
143. Whitton P. Inflammation as a causitive factor in the aetiology of Parkinson's disease. British Journal of Pharmacology 2007, 150(8):963-976.
144. Williams A., Ramsden D. Autotoxicity, methylation and a road to the prevention of Parkinson's disease. Journal of Clinical Neuroscience 2005, 12(1):6-11.
145. Wilms H., Claasen J., Rohl C., Sievers J., Deuschl G., Lucius R. Involvement of benzodiazepine receptors in neuroinflammatory and neurodegenerative diseases: Evidence from activated microglial cells in vitro. Neurobiology of Disease 2003, 14(3):417-424.
146. Wilms H., Rosenstiel P., Sievers J., Deuschl G., Zecca L., Lucius R. Activation of microglia by human neuromelanin is NF-KB-dependent and involves p38 mitogen-activated protein kinase: Implications for Parkinson's disease. Federation of American Societies for Experimental Biology 2003, 17(3):500-502.
147. Wu X.-F., Block M.L., Zhang W., Qin L., Wilson B., Zhang W.-Q., et al. The role of microglia in paraquat-induced dopaminergic neurotoxicity. Antioxidants and Redox Signaling 2005, 7(5-6):654-661.
148. Wu Z., Hayashi Y., Zhang J., Nakanishi H. Involvement of prostaglandin E2 released from leptomeningeal cells in increased expression of transforming growth factor-beta in glial cells and cortical neurons during systemic inflammation. Journal of Neuroscience Research 2007, 85(1):184-192.
149. Wu D.C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. Journal of Neuroscience 2002, 22(5):1763-1771.
150. Wu Z., Tokuda Y., Zhang X., Nakanishi H. Age-dependent responses of glial cells and leptomeninges during systemic inflammation. Neurobiology of Disease 2008, 32(3):543-551.
151. Wu Z., Zhang J., Nakanishi H. Leptomeningeal cells activate microglia and astrocytes to induce IL-10 production by releasing pro-inflammatory cytokines during systemic inflammation. Journal of Neuroimmunology 2005, 167(1-2):90-98.
152. Yang L., Sugama S., Chirichigno J.W., Gregorio J., Lorenzl S., Shin D.H., et al. Minocycline enhances MPTP toxicity to dopaminergic neurons. Journal of Neuroscience Research 2003, 74(2):278-285.
153. Zhou F., Wu J.-Y., Sun X.-L., Yao H.-H., Ding J.-H., Hu G. Iptakalim alleviates rotenone-induced degeneration of dopaminergic neurons through inhibiting microglia-mediated neuroinflammation. Neuropsychopharmacology 2007, 32(12):2570-2580.